Racial and ethnic disparities in use of 17-alpha hydroxyprogesterone caproate for prevention of preterm birth Presented orally (abstract no. 18) at the 36th annual meeting of the Society for Maternal-Fetal Medicine, Atlanta, GA, Feb. 1-6, 2016.

American Journal of Obstetrics and Gynecology

Volumn 214, Issue 3, 2016, Pages 374.e1-374.e6

  Yee, Lynn M ^a   Liu, Lilly Y ^a   Sakowicz, Allie ^a   Bolden, Janelle R ^a   Miller, Emily S ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

17 alpha hydroxyprogesterone caproate; adherence; disparities; health services; preterm birth; preterm birth prevention; racial disparities

Indexed keywords

HYDROXYPROGESTERONE CAPROATE; PROGESTERONE; 17-ALPHA-HYDROXY-PROGESTERONE CAPROATE; ANTIESTROGEN; PROGESTERONE DERIVATIVE;

ADULT; ARTICLE; BLACK PERSON; COHORT ANALYSIS; CONTROLLED STUDY; ETHNIC DIFFERENCE; FEMALE; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PREMATURE LABOR; PRESCRIPTION; PRIORITY JOURNAL; RACE DIFFERENCE; RETROSPECTIVE STUDY; ADOLESCENT; AFRICAN AMERICAN; ASIAN AMERICAN; CAUCASIAN; DIRECTIVE COUNSELING; ETHNOLOGY; HEALTH CARE DISPARITY; HEALTH INSURANCE; HISPANIC; ILLINOIS; MEDICAID; MIDDLE AGED; PREGNANCY; PREMATURE BIRTH; STATISTICS AND NUMERICAL DATA; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AFRICAN AMERICANS; ASIAN AMERICANS; DIRECTIVE COUNSELING; ESTROGEN ANTAGONISTS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTHCARE DISPARITIES; HISPANIC AMERICANS; HUMANS; HYDROXYPROGESTERONES; ILLINOIS; INSURANCE, HEALTH; MEDICAID; MEDICATION ADHERENCE; MIDDLE AGED; PREGNANCY; PREMATURE BIRTH; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 84976896513     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2015.12.054     Document Type: Article

References (13)

1. American College of Obstetricians and Gynecologists Prediction and prevention of preterm birth. Practice bulletin no. 130 Obstet Gynecol 120 2012 964 973
2. R.L. Goldenberg, J.F. Culhane, J.D. Iams, and R. Romero Epidemiology and causes of preterm birth Lancet 371 2008 75 84
3. P.J. Meis, M.K. Klebanoff, E. Thom, and et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate N Engl J Med 348 2003 2379 2385
4. J. Bailit, R. Berkowitz, J.M. Thorp, K. Cleary, K. Hartmann, and B. Mercer Use of progesterone to prevent preterm birth at a tertiary care center J Reprod Med 52 2007 280 284
5. A. Turitz, J. Bastek, S. Purisch, M. Elovitz, and L. Levine Patient characteristics associated with 17-alpha-hydroxyprogesterone caproate use among a high-risk cohort Am J Obstet Gynecol 2015 Oct 28 pii: S0002-9378(15)01453-2. http://dx.doi.org/10.1016/j.ajog.2015.10.148. [Epub ahead of print]
6. C. Rittenberg, S. Sullivan, N. Istwan, D. Rhea, G. Stanziano, and R. Newman Clinical characteristics of women prescribed 17 alpha-hydroxyprogesterone caproate in the community setting Am J Obstet Gynecol 197 2007 262.e1 262.e4
7. B. Lucas, A. Poole-Yaeger, N. Istwan, G. Stanziano, D. Rhea, and M. Mason Pregnancy outcomes of managed Medicaid members prescribed home administration of 17 alpha-hydroxyprogesterone caproate Am J Perinatol 29 2012 489-86
8. A. Rebarber, L.A. Ferrara, M.L. Hanley, and et al. Increased recurrence of preterm delivery with early cessation of 17 alpha-hydroxyprogesterone caproate Am J Obstet Gynecol 196 2007 224.e1 224.e4
9. M.V. Mason, K.M. House, J. Linehan, C.A. Speers, L.M. Joseph, and R. Littlejohn Optimizing the use of 17P in pregnant managed Medicaid members Managed Care 17 2008 47 52
10. J. Timofeev, J. Singh, N. Istwan, D. Rhea, and R.W. Driggers Spontaneous preterm birth in African American and Caucasian women receiving 17 alpha-hydroxyprogesterone caproate Am J Perinatol 31 2014 55 60
11. V. Berghella for the Society for Maternal-Fetal Medicine Publications Committee Progesterone and preterm birth prevention: translating clinical trials data into clinical practice Am J Obstet Gynecol 206 2012 376 386
12. C.Y. Spong, P.J. Meis, E. Thom, and et al. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery Am J Obstet Gynecol 193 2005 1127 1131
13. P.J. Meis, M.K. Klebanoff, M.P. Dombrowski, and et al. Does progesterone treatment influence risk factors for recurrent preterm delivery? Obstet Gynecol 106 2005 557 561